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In 2008, dengue virus serotype 4 (DENV-4) emerged 
in northeastern Peru, causing a large outbreak and dis-
placing DENV-3, which had predominated for the previous 
6 years. Phylogenetic analysis of 2008 and 2009 isolates 
support their inclusion into DENV-4 genotype II, forming a 
lineage distinct from strains that had previously circulated 
in the region.
I
nfection by any 1 of 4 distinct dengue virus serotypes 
(DENV-1 through DENV-4) can result in disease mani-
festations ranging from asymptomatic or mild to severe 
outcomes, including dengue hemorrhagic fever (DHF) 
and dengue shock syndrome. Several lines of evidence 
point toward secondary infection by a heterologous sero-
type as one of the critical risk factors for DHF (1), under-
scoring the need to monitor circulating DENV serotypes 
and genotypes.
In Latin America, >30 countries and regions have re-
ported DENV circulation, totaling >900,000 dengue fever 
cases, 26,000 DHF cases, and 300 deaths in 2007 (2). Fol-
lowing the breakdown of a hemisphere-wide Aedes aegypti 
mosquito eradication campaign conducted in the mid-20th 
century, vector populations expanded and all 4 DENV se-
rotypes reemerged or were reintroduced into the Western 
Hemisphere. Outbreaks of DENV-2 and DENV-3 were 
ﬁ  rst detected in the 1960s, followed by the introduction of 
DENV-1 in 1977 and DENV-4 in 1981 (3,4).
Since its introduction into the Americas in 1981, 
DENV-4 has circulated continuously in the Caribbean ba-
sin (5) and northern South America with little evidence of 
widespread transmission further south into the continent 
during the past 25 years (4,6,7). We report the emergence 
of DENV-4 strains belonging to genotype II in the tropical 
rainforest and coastal regions of northern Peru, replacing 
DENV-3 subtype III (8) as the predominant strain in the 
region.
The Study
Patients with acute, undifferentiated, febrile illness were 
recruited into a clinic-based surveillance study conducted 
jointly by the US Naval Medical Research Center Detach-
ment (NMRCD) and the Peruvian and Ecuadorian Institutes 
of Health (Figure 1). Study protocols (NMRCD.2000.0006 
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Figure 1. Map of study sites in Ecuador, Peru, and Venezuela. 
The study in Peru and Ecuador was operated jointly by the US 
Naval Medical Research Center Detachment with each country’s 
Institutes of Health. Samples from Venezuela were collected in 
and around Maracay through the Aragua State Epidemiologic 
Surveillance Program from patients with suspected dengue virus 
(DENV) infection. Cities denoted by ﬁ   lled circles indicate study 
sites where DENV serotype 4 strains were isolated, whereas open 
circles denote active study sites where no DENV–4 circulation was 
detected during the course of the study.[Peru] and NMRCD.2001.0002 [Ecuador]) were approved 
by the Naval Medical Research Center Institutional Review 
Boards in compliance with all US federal regulations gov-
erning the protection of human subjects.
Patient sera were injected onto African green monkey 
Vero cells or Ae. albopictus C6/36 cells and examined for 
a range of arboviruses, including all 4 DENV serotypes, 
by immunoﬂ  uorescent assay. From 2000 through 2008, 
DENV-3 (1,572 isolates) was the dominant serotype in 
circulation in the study sites, followed by DENV-1 (205 
isolates) and DENV-2 (87 isolates). From the initiation of 
the study in May 2000 until February 2006, DENV-4 circu-
lation was rarely detected in the NMRCD-afﬁ  liated study 
sites in either country; the exceptions were a small number 
of isolates in 2000 in Tumbes, Peru (n = 2) and Guyaquil, 
Ecuador (n = 6).
Low-level DENV-4 transmission was again detected 
in Ecuador and coastal Peru during 2006 and 2007, in iso-
lates from patients in Tumbes, Trujillo, and Guayaquil, 
none of whom had reported recent history of travel outside 
their respective areas. DENV-4 continued to circulate in 
sites along the northern coast of Peru in 2008 and 2009, in 
co-circulation with DENV-1. In February 2008, DENV-4 
spread to the cities of Iquitos and Yurimaguas, located in 
the Loreto Department in the tropical rainforest region of 
northeastern Peru. By October 2008, DENV-4 had nearly 
completely displaced DENV-3, which had been the only 
serotype detected in the region during the previous 3 years. 
Nine (56%) of 16 DENV isolates obtained from febrile pa-
tients in August 2008, 55 (85%) of 65 isolates obtained in 
September 2008, and 305 (98%) of 311 isolates obtained 
from October 2008 through February 2009 were DENV-4. 
After the introduction of DENV-4, the total number of 
DENV-3 isolates decreased during peak months of DENV 
transmission (October through February) from 176 during 
2006–2007 and 420 during 2007–2008 to <10 isolates dur-
ing the same period in 2008–2009. More recently (March 
2009), DENV-4 strains have spread south to Lima, the 
capital city of Peru, causing a small, localized outbreak on 
a military base.
To characterize the DENV-4 isolates, a 1,485-bp se-
quence covering the entire mature envelope (E) gene was 
ampliﬁ  ed and sequenced from a representative set of vi-
ruses from Guayaquil (n = 6), Tumbes (n = 6), Piura (n = 
2), Trujillo (n = 1), Iquitos (n = 9), Yurimaguas (n = 7), 
and Lima (n = 2), all collected during 2000 through 2009. 
Isolates collected in Peru since 2006 shared >99.5% nucle-
otide identity but exhibited <97% identity with DENV-4 
strains collected in Ecuador and coastal Peru in 2000. At 
the amino acid level, the 2006–2009 isolates were nearly 
invariant, with <1 amino acid difference.
For further characterization, the DENV-4 strains 
from Ecuador and Peru were compared with DENV-4 se-
quences from Latin America (9,10) and Southeast Asia 
(11) available from the GenBank database. In addition, 
to provide a wider array of recent isolates from the Ca-
ribbean region, DENV-4 isolated from febrile patients in 
Aragua State, Venezuela (n = 15) collected during 2000 
through 2007 were sequenced. Based on phylogenetic 
analyses, all DENV-4 isolates belong to genotype II (data 
not shown), although the 2006–2009 isolates segregated 
into a markedly different clade than the strains from 2000 
(Figure 2). The 2000 isolates clustered more closely with 
a previous 1994 Ecuador isolate (9), related to the initial 
1981 Caribbean introduction DENV-4 strains (designated 
as subtype A). The 2006–2009 isolates were most closely 
related to recent DENV-4 isolates from Venezuela, with as 
low as 0.8% nucleotide divergence, and formed a lineage 
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Figure 2. Phylogenetic analysis of the envelope gene of dengue 
virus serotype 4 (DENV–4) strains from Ecuador, Peru, and 
Venezuela. Similar topologies were observed from neighbor-joining 
(depicted), maximum likelihood, and maximum parsimony analyses, 
implemented in PAUP* v.4.0b10 (12). The general time reversible 
model of evolution was used for neighbor-joining and maximum-
likelihood analyses. DENV-4 genotype I strains (not shown) 
were included as an outgroup. Bootstrap values (based on 1,000 
replicates) >65 are shown at major nodes. Isolates ﬁ  rst reported 
in this study are shown in boldface and with sample identiﬁ  cation 
code. Some sequenced isolates from Peru and Venezuela that 
share high nucleotide identity (>99.7%) with depicted strains were 
omitted to reduce redundancy and improve clarity of the ﬁ  gure. 
Sequences were deposited in the GenBank database under the 
accession nos. GQ139572–GQ139577 (Ecuador), GQ139547–
GQ139571 (Peru), and GQ139578–GQ139591 (Venezuela). Scale 
bar indicates number of nucleotide substitutions per site.DENV-4 in Northeastern Peru
distinct from previously published DENV-4 Caribbean 
basin strains (9,10), with strong bootstrap support (Figure 
2). This lineage is distinguished from previously reported 
DENV-4 genotype II strains by 3 conserved amino acid 
variations in the E protein: S64L, A235T, and S403A.
Conclusions
We report DENV-4 expanding rapidly through north-
ern Peru, particularly in the Loreto Department in the tropi-
cal rainforest region, spreading through a population im-
munologically naïve to this serotype. In the past 2 decades, 
populations in northern Peru have been exposed to the 
other 3 DENV serotypes, thus increasing the possibility for 
severe disease, including DHF. In Iquitos, DHF was ﬁ  rst 
reported during a DENV-3 epidemic in 2004 (M. Sihuincha 
and C. Rocha, pers. comm.). DHF had not been observed 
after the introduction of DENV-2 despite large numbers of 
infected residents (13), presumably due to cross-protection 
afforded by prior infection with DENV-1 (14). For the cur-
rently circulating lineage of DENV-4, the levels of either 
cross-protection or antibody-dependent enhancement of in-
fection resulting from prior heterologous infection remain 
to be determined.
The mechanisms responsible for DENV-3 displace-
ment in Loreto are unclear. Following several years of 
DENV-3 circulation in the region, serotype-speciﬁ  c anti-
body prevalence is high (≈45% of the population, based 
on virus neutralization assays [T.J. Kochel, unpub. data]). 
However, it is unlikely that herd immunity is sufﬁ  cient to 
explain the dramatic decrease in DENV-3 transmission. The 
presence of broadly cross-protective antibodies during the 
acute and early convalescent phases following DENV-4 in-
fection, when combined with the large number of DENV-3 
immune persons, could suppress transmission of DENV-3 
strains (15). Another possibility is serotype competition 
within the vector species. Analysis of virus strains from Ae. 
aegypti mosquitoes collected during the transitional period 
could help elucidate whether such intertypic competition 
is occurring.
Genetically, the 2006–2009 isolates analyzed in this 
study do not appear to be related to viruses collected from 
Ecuador and northern Peru during 2000, which were simi-
lar to the initial Latin American introduction strains (Fig-
ure 2). Instead the 2006–2009 isolates were most closely 
related to viruses from Venezuela collected during 2000 
through 2007, forming a lineage distinct from the DENV-4 
genotype II B4 lineage (10). Genetic conservation among 
isolates from Peru and similarity with isolates from Ven-
ezuela support an introduction event into northern Peru 
and Ecuador from the northern region of South America 
before 2006, and a subsequent introduction from coastal 
Peru into Loreto, although more data from other regions 
of South America and the Caribbean basin would be nec-
essary to more clearly delineate the geographic spread of 
this virus strain.   
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